CSIMarket Company Name, Ticker, Industry, else..
 
Tempest Therapeutics Inc   (NASDAQ: TPST)
 
Price: $1.1000 $0.05 4.762%
Day's High: $1.1200000047683716 Week Perf: 1.85 %
Day's Low: $ 1.05 30 Day Perf: 24.01 %
Volume (M): 125,712 52 Wk High: $ 12.23
Volume (M$): $ 0 52 Wk Avg: $3.77
Open: $1.05 52 Wk Low: $0.84



 Market Capitalization (Millions $) 12
 Shares Outstanding (Millions) 11
 Employees 4
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -43
 Cash Flow (TTM) (Millions $) -20
 Capital Exp. (TTM) (Millions $) 0

Business Description


Tempest Therapeutics Inc is a biotechnology company that specializes in the discovery and development of novel small molecule therapeutics. The company focuses on targeting the immune system to address various forms of cancer. Tempest Therapeutics aims to develop innovative treatments that can modify the tumor microenvironment and enhance immune responses against cancer cells. Their research is centered around understanding the intricate interplay between the immune system and cancer to develop effective therapies that can improve patient outcomes.


   Company Address: 2000 Sierra Point Parkway Brisbane 94005 CA
   Company Phone Number: 798-8589   Stock Exchange / Ticker: NASDAQ TPST


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY        0.13% 
JNJ        1.93% 
LLY   -2.47%    
MRK   -0.95%    
REGN        4.57% 
VRTX        1.73% 
• View Complete Report
   



Product Service News

Tempest in a Teacup The Promise of Amezalpat Sparks Hope Amidst Challenges

Published Thu, Jun 5 2025 12:29 PM UTC

In a groundbreaking turn of events, Tempest Therapeutics, Inc. has just been awarded Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for its innovative treatment, amezalpat (TPST1120), aimed at combating hepatocellular carcinoma (HCC), the most prevalent form of liver cancer. This recognition not only showcases the potential of amezalpat a selective PPAR...
Shares

Tempest Therapeutics Unveils Key Inducement Grant: Implications for Investor Outlook and Share Value

Published Fri, Feb 7 2025 9:30 PM UTC

Understanding the AnnouncementOn February 7, 2025, Tempest Therapeutics, Inc. (NASDAQ: TPST), a clinical-stage biotechnology company renowned for its innovative approaches to cancer treatment, made an important debut concerning its employee compensation strategy. The company disclosed that it had granted stock options evenly spread, amounting to a total of 45,000 shares of i...
Clinical Study

In a significant move that reflects its ongoing commitment to fostering talent and promoting growth within ...

Published Fri, Dec 6 2024 9:30 PM UTC

Tempest Therapeutics Expands Workforce Incentives with Stock Option Grants under Nasdaq Listing Rule 5635(c)(4) In a significant move that reflects its ongoing commitment to fostering talent and promoting growth within its ranks, Tempest Therapeutics, Inc. (Nasdaq: TPST), a pioneering clinical-stage biotechnology firm specializing in the development of first-in-class targete...
Contract

Advancement of Amezalpat Combination Therapy in First-Line Hepatocellular Carcinoma Tempests Collaboration with Roche

Published Thu, Oct 10 2024 11:01 AM UTC

: Tempest Therapeutics, a biopharmaceutical company focused on innovative cancer therapies, has announced a significant partnership with Roche to advance their Amezalpat combination therapy into a pivotal Phase 3 clinical trial for the treatment of first-line hepatocellular carcinoma (HCC). This article outlines the implications of this collaboration, the details of the upco...
Stock Market Announcement

Tempest Therapeutics Amplifies Stockholder Protection: The Implications of Extended Rights Plan

Published Thu, Oct 10 2024 11:00 AM UTC

Tempest Therapeutics Extends Its Stockholder Rights Plan: What It Means for InvestorsOn October 10, 2024, Tempest Therapeutics, Inc. (Nasdaq: TPST), a rising star in the biotechnology sector focusing on innovative cancer therapies, announced a significant amendment to its existing limited duration stockholder rights plan. This strategic decision by the company’s Board of D...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 14.63
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.87
Working Capital Ratio 1.18
Leverage Ratio (MRQ) 12.08
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -6.36 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 0.17 $
Book Value 0.08 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -10,774,500
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.